Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Plasma YKL-40, a new biomarker for atrial fibrillation?

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Harvard

APA

CBE

MLA

Vancouver

Author

Bibtex

@article{14b653d93e614742b40e072871163eb5,
title = "Plasma YKL-40, a new biomarker for atrial fibrillation?",
abstract = "AIMS: The aim of this study was to determine changes in a new potential biomarker plasma YKL-40 in patients with atrial fibrillation (AF) before and after electrical cardioversion (CV). METHODS AND RESULTS: Plasma concentrations of YKL-40 were measured in 56 patients (mean age 65 years, range 34-84) with persistent AF (lasting mean 128 days, range 14-960), in 19 age-matched patients with permanent AF, and in 19 healthy subjects. The patients with persistent AF underwent CV. Plasma YKL-40 was measured prior to CV, and at follow-up after 24 h, 30 and 180 days. Patients with persistent AF had lower plasma YKL-40 than patients with permanent AF [70 microg/L (42-105)] vs. [138 microg/L (48-225)] (P = 0.003), and higher levels than healthy subjects [41 microg/L (29-52)] (P = 0.001). Patients (n = 22) who were still in sinus rhythm (SR) at follow-up 30 days after CV had unchanged plasma YKL-40 compared with baseline levels. The baseline levels of YKL-40 were correlated to the levels of IL-6, but not to high sensitivity C-reactive protein. CONCLUSION: Patients with AF have significantly elevated levels of YKL-40. YKL-40 was not a significant predictor of successful CV to SR. Plasma levels of YKL-40 did not fall after restoration of SR.",
keywords = "Adult, Aged, Aged, 80 and over, Atrial Fibrillation, Biological Markers, Denmark, Female, Glycoproteins, Humans, Male, Middle Aged, Myocarditis, Prevalence, Risk Assessment, Risk Factors",
author = "Henningsen, {Kristoffer Mads} and Therkelsen, {Susette Krohn} and Johansen, {Julia Sidenius} and Helle Bruunsgaard and Svendsen, {Jesper Hastrup}",
year = "2009",
doi = "10.1093/europace/eup103",
language = "English",
volume = "11",
pages = "1032--6",
journal = "Europace",
issn = "1099-5129",
publisher = "Oxford University Press",
number = "8",

}

RIS

TY - JOUR

T1 - Plasma YKL-40, a new biomarker for atrial fibrillation?

AU - Henningsen, Kristoffer Mads

AU - Therkelsen, Susette Krohn

AU - Johansen, Julia Sidenius

AU - Bruunsgaard, Helle

AU - Svendsen, Jesper Hastrup

PY - 2009

Y1 - 2009

N2 - AIMS: The aim of this study was to determine changes in a new potential biomarker plasma YKL-40 in patients with atrial fibrillation (AF) before and after electrical cardioversion (CV). METHODS AND RESULTS: Plasma concentrations of YKL-40 were measured in 56 patients (mean age 65 years, range 34-84) with persistent AF (lasting mean 128 days, range 14-960), in 19 age-matched patients with permanent AF, and in 19 healthy subjects. The patients with persistent AF underwent CV. Plasma YKL-40 was measured prior to CV, and at follow-up after 24 h, 30 and 180 days. Patients with persistent AF had lower plasma YKL-40 than patients with permanent AF [70 microg/L (42-105)] vs. [138 microg/L (48-225)] (P = 0.003), and higher levels than healthy subjects [41 microg/L (29-52)] (P = 0.001). Patients (n = 22) who were still in sinus rhythm (SR) at follow-up 30 days after CV had unchanged plasma YKL-40 compared with baseline levels. The baseline levels of YKL-40 were correlated to the levels of IL-6, but not to high sensitivity C-reactive protein. CONCLUSION: Patients with AF have significantly elevated levels of YKL-40. YKL-40 was not a significant predictor of successful CV to SR. Plasma levels of YKL-40 did not fall after restoration of SR.

AB - AIMS: The aim of this study was to determine changes in a new potential biomarker plasma YKL-40 in patients with atrial fibrillation (AF) before and after electrical cardioversion (CV). METHODS AND RESULTS: Plasma concentrations of YKL-40 were measured in 56 patients (mean age 65 years, range 34-84) with persistent AF (lasting mean 128 days, range 14-960), in 19 age-matched patients with permanent AF, and in 19 healthy subjects. The patients with persistent AF underwent CV. Plasma YKL-40 was measured prior to CV, and at follow-up after 24 h, 30 and 180 days. Patients with persistent AF had lower plasma YKL-40 than patients with permanent AF [70 microg/L (42-105)] vs. [138 microg/L (48-225)] (P = 0.003), and higher levels than healthy subjects [41 microg/L (29-52)] (P = 0.001). Patients (n = 22) who were still in sinus rhythm (SR) at follow-up 30 days after CV had unchanged plasma YKL-40 compared with baseline levels. The baseline levels of YKL-40 were correlated to the levels of IL-6, but not to high sensitivity C-reactive protein. CONCLUSION: Patients with AF have significantly elevated levels of YKL-40. YKL-40 was not a significant predictor of successful CV to SR. Plasma levels of YKL-40 did not fall after restoration of SR.

KW - Adult

KW - Aged

KW - Aged, 80 and over

KW - Atrial Fibrillation

KW - Biological Markers

KW - Denmark

KW - Female

KW - Glycoproteins

KW - Humans

KW - Male

KW - Middle Aged

KW - Myocarditis

KW - Prevalence

KW - Risk Assessment

KW - Risk Factors

U2 - 10.1093/europace/eup103

DO - 10.1093/europace/eup103

M3 - Journal article

VL - 11

SP - 1032

EP - 1036

JO - Europace

JF - Europace

SN - 1099-5129

IS - 8

ER -

ID: 32556732